The results from this study were consistent with pre clinical findings.

‘These positive results are an important milestone for the -001-001 program and Cerenis ‘ approach to developing potent HDL mimetics said Jean-Louis Dasseux, CEO of Cerenis. ‘The data strongly support further clinical development CER-001 for the treatment of patients with high-risk atherosclerosis, including acute coronary syndromes. ‘.. The results from this study were consistent with pre – clinical findings, evidence of dose – related cholesterol mobilization, as well as evidence of substantial increases in HDL cholesterol levels. Because of these properties, we believe CER CER-001 to promote reverse cholesterol transport and stimulate cholesterol removal in patients.

Haskins Laboratories was established in 1935 by the late Dr. Caryl P. Haskins founded. The leading research firm in New Haven, Connecticut since 1970, when with Yale University and the University of Connecticut formalized affiliations. The Laboratories ‘ primary research focuses on the science of the spoken and written word.I.. Jay I. Meltzer MD, Clinical Specialist in Hypertension the Nephrologie Division of the Columbia College of Physicians and Surgeons, is Dr Julius Dr. Julius ‘ reply he remain skeptical the study design, to the change the terminology and the. Interpretation of the data. Most importantly, it includes figures of the original publication of on Julius et al create, and from the critical figure to permit the to allow the TROPHY the final report the opportunity to judge for themselves whether the data supporting the statement that blood pressure was prevented.

Other Posts From "potency":

Related Posts